Acute Renal Failure under Dasatinib Therapy

ÖZKURT S., Temiz G., AÇIKALIN M. F., SOYDAN M.

RENAL FAILURE, cilt.32, sa.1, ss.147-149, 2010 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 32 Sayı: 1
  • Basım Tarihi: 2010
  • Doi Numarası: 10.3109/08860220903391226
  • Dergi Adı: RENAL FAILURE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.147-149
  • Anahtar Kelimeler: acute renal failure, chronic myeloid leukemia, tyrosine kinase inhibitors, dasatinib, IMATINIB MESYLATE TREATMENT, TYROSINE KINASE, INHIBITOR, SECONDARY, LEUKEMIA, AMN107
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

Dasatinib is a second-generation tyrosine kinase inhibitor that is approved for the treatment of imatinib-resistant or imatinib-intolerant chronic myeloid leukemia. It has a 325 times stronger in vitro activity against to native BCR-ABL when comparing with imatinib. Little is known about the effects of dasatinib on renal function. A literature review revealed only one case with imatinib-resistant chronic myeloid leukemia that developed renal failure after being placed on dasatinib therapy. Here we report a patient with imatinib-resistant chronic myeloid leukemia who developed gastroenteritis and acute renal failure after a short time from the initiation of dasatinib therapy. After dasatinib interruption, these side effects resolved completely in days. In summary, dasatinib is a potent drug in the treatment of chronic myeloid leukemia, but close clinical monitoring and the timely interruption of the therapy in patients who developed acute renal failure are warranted.